Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Benchmark Maintains Buy on Snap, Lowers Price Target to $15

Benchmark analyst Mark Zgutowicz maintains Snap (NYSE:SNAP) with a Buy and lowers the price target from $20 to $15.

byBenzinga Newsdesk

July 22, 2022

1 minute read

Benchmark analyst Mark Zgutowicz maintains Snap (NYSE:SNAP) with a Buy and lowers the price target from $20 to $15.

Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

By Vandana Singh

August 24, 6:16 AM

Theravance Biopharma Inc’s (NASDAQ:TBPH) Izencitinib, a “gut-selective” JAK inhibitor developed for ulcerative colitis and Crohn’s disease, failed a key Phase…

JNJ

News
Tech

Qualcomm, GlobalFoundries Extend 5G RF Partnership

By Anusuya Lahiri

September 15, 3:38 PM

Qualcomm Inc (NASDAQ:QCOM) subsidiary Qualcomm Global Trading PTE Ltd and GlobalFoundries (GF) extended their RF collaboration on 5G multi-Gigabit speed RF…

QCOM

Cognyte Software Shares Drop On Weak Q3 Outlook

By Anusuya Lahiri

September 20, 9:05 AM

Security analytics software firm Cognyte Software Ltd (NASDAQ:CGNT) reported second-quarter revenue growth of 9.5% year-on-year on a non-GAAP basis to $116.38 million,…

CGNT

Earnings Scheduled For March 28, 2022

By Benzinga Insights

March 28, 4:45 AM

Companies Reporting Before The Bell • LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million.

ABOS

Benchmark Maintains Buy on Snap, Lowers Price Target to $15

Related Posts

Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

Qualcomm, GlobalFoundries Extend 5G RF Partnership

Cognyte Software Shares Drop On Weak Q3 Outlook

Earnings Scheduled For March 28, 2022